Bringing The Next-Generation Of Antibiotics
to win the war against resistant bacteria
Omnix Medical is a biopharmaceutical company
Founded in 2015, Omnix Medical is developing an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria.
Omnix’s technology can tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Our exceptional technology offers a first-in-its-class drug
Moving together towards a better future
MOVING TOGETHER TOWARDS A BETTER FUTURE
WE AT OMNIX MEDICAL
ARE ALWAYS LOOKING FOR EXTRAORDINARY PEOPLE TO JOIN OUR TEAM
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S.
OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office
We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
OMN6 demonstrates safety and tolerability at clinically significant dose levels JERUSALEM, Israel, May 8th, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for